Michal Juraska, Hongjun Bai, Allan C deCamp, Craig A Magaret, Li Li, Kevin Gillespie, Lindsay N Carpp, Elena E Giorgi, James Ludwig, Cindy Molitor, Aaron Hudson, Brian D Williamson, Nicole Espy, Brian Simpkins, Erika Rudnicki, Danica Shao, Raabya Rossenkhan, Paul T Edlefsen, Dylan H Westfall, Wenjie Deng, Lennie Chen, Hong Zhao, Tanmoy Bhattacharya, Alec Pankow, Ben Murrell, Anna Yssel, David Matten, Talita York, Nicolas Beaume, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Ruwayhida Thebus, Shelly T Karuna, Lynn Morris, David C Montefiori, John A Hural, Myron S Cohen, Lawrence Corey, Morgane Rolland, Peter B Gilbert, Carolyn Williamson, James I Mullins
In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition diagnosis varied according to the HIV-1 Envelope (Env) neutralization sensitivity to VRC01, as measured by 80% inhibitory concentration (IC80). Here, we performed a genotypic sieve analysis, a complementary approach to gaining insight into correlates of protection that assesses how PE varies with HIV-1 sequence features...
January 23, 2024: Proceedings of the National Academy of Sciences of the United States of America